blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2958550

EP2958550 - ORAL FORMULATION AND SUSPENSION OF AN ONCOLOGY DRUG [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.06.2023
Database last updated on 31.08.2024
FormerThe patent has been granted
Status updated on  15.07.2022
FormerGrant of patent is intended
Status updated on  22.02.2022
FormerExamination is in progress
Status updated on  03.12.2019
Most recent event   Tooltip16.02.2024Lapse of the patent in a contracting state
New state(s): BE		published on 20.03.2024  [2024/12]
Applicant(s)For all designated states
Sun Pharmaceutical Industries Limited
SPARC, TANDALJA
Vadodara, Gujarat-390012 / IN
[2022/32]
Former [2019/01]For all designated states
Sun Pharma Global FZE
43, Block Y, SAIF Zone
P.O. Box 122304
Sharjah / AE
Former [2016/01]For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
Inventor(s)01 / DECAUDIN, Céline
c/o Novartis Pharma AG
Novartis Campus
Virchow 6-4th
4056 Basel / CH
02 / ROGUE, Vincent
c/o Novartis Pharma AG
Forum 1
Novartis Campus
4056 Basel / CH
 [2022/33]
Former [2016/01]01 / DECAUDIN, Celine
c/o Novartis Pharma AG
Forum 1
Novartis Campus
CH-4056 Basel / CH
02 / ROGUE, Vincent
c/o Novartis Pharma AG
Forum 1
Novartis Campus
CH-4056 Basel / CH
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[2022/33]
Former [2016/01]Rudge, Sewkian
Novartis Pharma AG
Patent Department
4002 Basel / CH
Application number, filing date14710642.121.02.2014
[2016/01]
WO2014IB59161
Priority number, dateUS201361768803P25.02.2013         Original published format: US 201361768803 P
[2016/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014128661
Date:28.08.2014
Language:EN
[2014/35]
Type: A1 Application with search report 
No.:EP2958550
Date:30.12.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 28.08.2014 takes the place of the publication of the European patent application.
[2015/53]
Type: B1 Patent specification 
No.:EP2958550
Date:17.08.2022
Language:EN
[2022/33]
Search report(s)International search report - published on:EP28.08.2014
ClassificationIPC:A61K9/10, A61K47/14, A61K31/5377, A61P35/00
[2022/10]
CPC:
A61K31/5377 (EP,IL,US); A61K47/02 (IL,US); A61K47/12 (IL,US);
A61K47/14 (EP,IL,US); A61K47/26 (IL,US); A61K47/38 (IL,US);
A61K9/0095 (EP,IL,US); A61K9/10 (EP,IL,US); A61P35/00 (EP,IL);
B65D81/32 (IL,US) (-)
Former IPC [2016/01]A61K9/10, A61K47/14, A61K31/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/01]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ORALE FORMULIERUNG UND SUSPENSION EINES ONKOLOGISCHEN ARZNEIMITTELS[2016/01]
English:ORAL FORMULATION AND SUSPENSION OF AN ONCOLOGY DRUG[2016/01]
French:FORMULATION ET SUSPENSION À USAGE ORAL D'UN MÉDICAMENT ONCOLOGIQUE[2016/01]
Entry into regional phase25.09.2015National basic fee paid 
25.09.2015Designation fee(s) paid 
25.09.2015Examination fee paid 
Examination procedure02.09.2015Amendment by applicant (claims and/or description)
25.09.2015Examination requested  [2015/53]
06.12.2019Despatch of a communication from the examining division (Time limit: M06)
07.06.2020Reply to a communication from the examining division
26.05.2021Despatch of a communication from the examining division (Time limit: M04)
05.10.2021Reply to a communication from the examining division
23.02.2022Communication of intention to grant the patent
05.07.2022Fee for grant paid
05.07.2022Fee for publishing/printing paid
05.07.2022Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  06.12.2019
Opposition(s)19.05.2023No opposition filed within time limit [2023/30]
Fees paidRenewal fee
10.02.2016Renewal fee patent year 03
10.02.2017Renewal fee patent year 04
27.02.2018Renewal fee patent year 05
28.02.2019Renewal fee patent year 06
02.03.2020Renewal fee patent year 07
25.02.2021Renewal fee patent year 08
25.02.2022Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL17.08.2022
AT17.08.2022
CZ17.08.2022
DK17.08.2022
EE17.08.2022
FI17.08.2022
HR17.08.2022
LT17.08.2022
LV17.08.2022
MC17.08.2022
RS17.08.2022
SE17.08.2022
SI17.08.2022
SK17.08.2022
SM17.08.2022
NO17.11.2022
GR18.11.2022
IS17.12.2022
PT19.12.2022
IE21.02.2023
LU21.02.2023
BE28.02.2023
[2024/12]
Former [2024/08]AL17.08.2022
AT17.08.2022
CZ17.08.2022
DK17.08.2022
EE17.08.2022
FI17.08.2022
HR17.08.2022
LT17.08.2022
LV17.08.2022
MC17.08.2022
RS17.08.2022
SE17.08.2022
SI17.08.2022
SK17.08.2022
SM17.08.2022
NO17.11.2022
GR18.11.2022
IS17.12.2022
PT19.12.2022
IE21.02.2023
LU21.02.2023
Former [2023/49]AL17.08.2022
AT17.08.2022
CZ17.08.2022
DK17.08.2022
EE17.08.2022
FI17.08.2022
HR17.08.2022
LT17.08.2022
LV17.08.2022
MC17.08.2022
RS17.08.2022
SE17.08.2022
SI17.08.2022
SK17.08.2022
SM17.08.2022
NO17.11.2022
GR18.11.2022
IS17.12.2022
PT19.12.2022
LU21.02.2023
Former [2023/44]AL17.08.2022
AT17.08.2022
CZ17.08.2022
DK17.08.2022
EE17.08.2022
FI17.08.2022
HR17.08.2022
LT17.08.2022
LV17.08.2022
MC17.08.2022
RS17.08.2022
SE17.08.2022
SI17.08.2022
SK17.08.2022
SM17.08.2022
NO17.11.2022
GR18.11.2022
IS17.12.2022
PT19.12.2022
Former [2023/37]AL17.08.2022
AT17.08.2022
CZ17.08.2022
DK17.08.2022
EE17.08.2022
FI17.08.2022
HR17.08.2022
LT17.08.2022
LV17.08.2022
RS17.08.2022
SE17.08.2022
SI17.08.2022
SK17.08.2022
SM17.08.2022
NO17.11.2022
GR18.11.2022
IS17.12.2022
PT19.12.2022
Former [2023/29]AL17.08.2022
AT17.08.2022
CZ17.08.2022
DK17.08.2022
EE17.08.2022
FI17.08.2022
HR17.08.2022
LT17.08.2022
LV17.08.2022
RS17.08.2022
SE17.08.2022
SK17.08.2022
SM17.08.2022
NO17.11.2022
GR18.11.2022
IS17.12.2022
PT19.12.2022
Former [2023/23]AT17.08.2022
CZ17.08.2022
DK17.08.2022
EE17.08.2022
FI17.08.2022
HR17.08.2022
LT17.08.2022
LV17.08.2022
RS17.08.2022
SE17.08.2022
SK17.08.2022
SM17.08.2022
NO17.11.2022
GR18.11.2022
IS17.12.2022
PT19.12.2022
Former [2023/22]AT17.08.2022
CZ17.08.2022
DK17.08.2022
FI17.08.2022
HR17.08.2022
LT17.08.2022
LV17.08.2022
RS17.08.2022
SE17.08.2022
SM17.08.2022
NO17.11.2022
GR18.11.2022
IS17.12.2022
PT19.12.2022
Former [2023/21]DK17.08.2022
FI17.08.2022
HR17.08.2022
LT17.08.2022
LV17.08.2022
RS17.08.2022
SE17.08.2022
SM17.08.2022
NO17.11.2022
GR18.11.2022
IS17.12.2022
PT19.12.2022
Former [2023/20]FI17.08.2022
HR17.08.2022
LT17.08.2022
LV17.08.2022
RS17.08.2022
SE17.08.2022
SM17.08.2022
NO17.11.2022
GR18.11.2022
IS17.12.2022
PT19.12.2022
Former [2023/12]FI17.08.2022
HR17.08.2022
LT17.08.2022
LV17.08.2022
RS17.08.2022
SE17.08.2022
NO17.11.2022
GR18.11.2022
IS17.12.2022
PT19.12.2022
Former [2023/10]FI17.08.2022
HR17.08.2022
LT17.08.2022
LV17.08.2022
RS17.08.2022
SE17.08.2022
NO17.11.2022
GR18.11.2022
PT19.12.2022
Former [2023/09]FI17.08.2022
LT17.08.2022
LV17.08.2022
RS17.08.2022
SE17.08.2022
NO17.11.2022
PT19.12.2022
Former [2023/08]FI17.08.2022
LT17.08.2022
RS17.08.2022
SE17.08.2022
NO17.11.2022
Cited inInternational search[XY]WO2010033481  (NOVARTIS AG [CH], et al) [X] 1,17 * page 2, paragraph 0005 * * examples 4, 10 * [Y] 1-3,17;
 [Y]US2012122866  (FRITZE ANDREAS [DE], et al) [Y] 1-3,17 * page 1, paragraph 0001 * * page 2, paragraph 0021 - page 4, paragraph 0063 ** page 6, paragraphs 0099-0100 *
by applicantWO2007US68292
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.